

Bibliografía

1. Monath TP, Gershman M, Staples, et al. Yellow fever vaccine. En: Plotkin SA, Orenstein WA, Offit PA, editores. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2012. p. 870-968.
2. Centers for Disease Control and Prevention. CDC health information for international travel 2018. New York: Oxford University Press; 2018. (Consultado en marzo de 2018.) Disponible en: <https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseasesrelated-to-travel/yellow-fever>
3. Quaresma JAS, Pagliari C, Medeiros DBA, et al. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23:305-18.
4. Garske T, Van Kerkhove MD, Yactayo S, et al.; Yellow Fever Expert Committee. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11:e1001638.
5. World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. Wkly Epidemiol Rec. 2013;88:269-83.
6. Ministerio de Sanidad, Servicios Sociales e Igualdad. Sanidad exterior. La salud también viaja. (Consultado en marzo de 2018.) Disponible en: <http://www.msc.es/profesionales/saludPublica/sanidadExterior/salud/home.htm>
7. European Centre for Disease Prevention and Control. Rapid risk assessment. Outbreak of yellow fever in Angola, Democratic Republic of Congo and Uganda: second update, 13 July 2016. Stockholm: ECDC; 2016.
8. Yellow fever: a global reckoning. Lancet. 2016;387:1348.
9. European Centre for Disease Prevention and Control.

Rapid risk assessment. Outbreak of yellow fever in Brazil: third update, 16 March 2018. Stockholm: ECDC; 2018.

10. Lee LA, Franzel L, Atwell J, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. *Vaccine*. 2013;31(Suppl 2):B61-B72.
11. World Health Organization. Amendment to International Health Regulations (2005), Annex 7 (yellow fever). Geneva: WHO; 2016.
12. Nascimento Silva JR, Camacho LA, Siqueira MM, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. *Vaccine*. 2011;29:6327-34.
13. World Health Organization. International Health Regulations, 2005. Geneva: WHO; 2008. (Consultado en marzo de 2018.) Disponible en: http://whqlibdoc.who.int/publications/2008/9789241580410_eng.pdf
14. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2010;59(RR-7):1-27.
15. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2012;30:5038-58.
16. Salisbury D, Ramsay M, editores. Chapter 35: Yellow fever. En: Green book: Immunisation against infectious disease. Public Health England, London. (Actualizado en abril de 2017; consultado en marzo de 2018.) Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/606642/green_book_chapter_35.pdf
17. Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective

- study. *Trans R Soc Trop Med Hyg.* 1993;87:337-9.
18. Tsai TF, Paul R, Lynberg MC, et al. Congenital yellow fever virus infection after immunization in pregnancy. *J Infect Dis.* 1993;168:1520-3.
 19. Tattevin P, Depatureaux AG, Chaplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. *AIDS.* 2004;18:825-7.
 20. Tanrıöver MD, Akar S, Türkçapar N, et al. Vaccination recommendations for adult patients with rheumatic diseases. *Eur J Rheumatol.* 2016;3:29-35.